In PepBank now:147 peptides, 6 blends and 13 other compounds97,577 study results from 17,383 studies8,473 clinical trialsUpdated
Comparing 2 peptides · Data version 308560
Swipe sideways to see every peptide.
| Peptide | Synthetic analog Cetrorelix | Natural fragment Kisspeptin-10 | |
|---|---|---|---|
| Identity | |||
| Kind | Synthetic analog | Natural fragment | |
| Area | Sexual health and hormones | Sexual health and hormones | |
| Evidence | |||
| Amount of evidence | 486 | 1,457 (plus 233 on natural levels, listed separately) | |
| Evidence level | Has results from studies in people | Has results from studies in people | |
| Safety | |||
| Safety results | 57 (55 in people) | 31 (0 in people) | |
| Status | |||
| Approval | |||
| Sport (WADA) | |||
| Registered trials | 95 · 8 active45 more mention it but do not test it | 17 · 3 active1 more mentions it but does not test it | |
Shared outcomes
From the regulatory data of each peptide.
The FDA label for Cetrotide says: “Prevention of premature LH surges during controlled ovarian stimulation”
Outcome groups with study results for at least two of these peptides. Counts include only results from studies that gave the peptide. Bar length is the number of results, on one scale. The bars show how much was studied, not how large an effect was. A peptide with more studies can look stronger here without being stronger. For results, see the randomized results above.
| Outcome group | Cetrorelix | Kisspeptin-10 |
|---|---|---|
| Sex hormones and fertilityReproductive and sexual health | 357334212 |
PepBank is a research reference. Talk to a doctor before you use any peptide.
Its most advanced trial is in phase 2. The FDA, the EMA and the other sources we use show no approval (as of 9 Oct 2026).
| Receptor activity and mechanismPharmacology | 224135 | 24214218910 |
|---|
| Adverse eventsWhole body | 5353 | 651 |
|---|
| Tumor growthReproductive and sexual health | 9612 | 49544 |
|---|
| Inflammation markersKidney and urinary | 761 | 352114 |
|---|
| PharmacokineticsPharmacology | 1111 | 651 |
|---|
| LipidsMetabolic and weight | 55 | 29920 |
|---|
| Bone and jointImmune and inflammation | 77 | 16115 |
|---|
| Sexual functionReproductive and sexual health | 11 | 1111 |
|---|
| Metabolic pathways and metabolomicsMetabolic and weight | 11 | 66 |
|---|
| Immune responseImmune and inflammation | 11 | 77 |
|---|
Each analog against its native parent, residue by residue. Substitutions, non-standard residues and modifications are marked. Calculated from the two sequences.
Cetrorelix differs from Gonadorelin at 5 positions.
What is different
Kisspeptin-10 is the same as Kisspeptin-54 (metastin) residues 45 to 54, with 1 added group.
What is different
Registered trials, ranked by phase (late phases first), then posted results and enrollment. Status is the registry status. Study results come from published studies. Results posted at ClinicalTrials.gov are shown on each trial page.
Top 3 of 95 trials, ranked by phase, then posted results and enrollment: 1 completed · 2 stopped early · 3 with posted results · source ClinicalTrials.gov (opens in a new tab)
AEterna Zentaris667 participantsMar 2007 to Dec 2009
Benign Prostatic Hypertrophy
Bart CJM Fauser617 participantsFeb 2009 to Oct 2012
In Vitro Fertilization · Intracytoplasmic Sperm Injection
AEterna Zentaris528 participantsMar 2008 to Aug 2009
Benign Prostatic Hypertrophy
45 more mention it but do not test it. They only measure it or name it in their text.
Top 3 of 17 trials, ranked by phase, then posted results and enrollment: 3 completed · source ClinicalTrials.gov (opens in a new tab)
Ghulam Nabi30 participants26 Jun 2014 to 5 Mar 2015
Reproductive Physiological Phenomena
Quaid-e-Azam University15 participants8 Aug 2014 to 5 Mar 2015
Sterility, Reproductive
Quaid-e-Azam University14 participants29 Oct 2013 to 10 Jan 2014
Kisspeptin Action on Insulin in Healthy Normal Men · Kisspeptin Action on Insulin in Obese Diabetic Men
1 more mentions it but does not test it. They only measure it or name it in their text.
For each outcome that two or more peptides have results for: the best result of a single randomized trial, on the same measure (the same kind of number, the same unit). When a trial has several dose arms, the cell shows the highest dose arm. The trials differ in people, length and dose, so a gap between two cells is not proof that one peptide works better.
| Outcome | Cetrorelix | Kisspeptin-10 |
|---|---|---|
| Sex hormones and fertilityEndocrine and hormonesCompared as: value in the arm that got the peptide, in iu/l | 2.8 IU/l LH on day 5, mean · cetrorelix group; SD 1.4 Dose studied: 0.25 mgn = 402009 | 9 IU/l LH · kisspeptin-10 Vehicle: 3.5 IU/l Dose studied: 4 µg/kg/h7 hn = 82020 |
2.8 IU/l
LH on day 5, mean · cetrorelix group; SD 1.4
Dose studied: 0.25 mgn = 402009
9 IU/l
LH · kisspeptin-10
Vehicle: 3.5 IU/l
Dose studied: 4 µg/kg/h7 hn = 82020
The other peptides have no randomized result on the same measure, so these results cannot be set side by side.
| Outcome | Cetrorelix | Kisspeptin-10 |
|---|---|---|
| Bone and jointImmune and inflammationCompared as: value in the arm that got the peptide, in points | −0.82 points DAS28-CRP reduction · Shown as a change. The study reports a das28-crp reduction of this size. Placebo: −0.57 points Dose studied: 5 mg/day on days 1 and 2; 3 mg/day on days 3-5n = 992014 |
No randomized trial result 16 results from other study designs. |
| Tumor growthReproductive and sexual healthCompared as: value in the arm that got the peptide, in % | −15.6% Mean uterine volume reduction, day 29 · Shown as a change. The study reports a mean uterine volume reduction, day 29 of this size. · cetrorelix 4 x 5 mg (SD 20.2) Placebo (SD 32.1): −5.1% Dose studied: 5 mg on days 1, 8, 15 and 224 weeksn not reported2007 | No randomized trial result 49 results from other study designs. |
|---|
| Adverse eventsReproductive and sexual healthCompared as: value in the arm that got the peptide, in % | 1.6% Patients not given hCG for threatening OHSS n = 2732000 | No randomized trial result 6 results from other study designs. |
|---|
−0.82 points
DAS28-CRP reduction · Shown as a change. The study reports a das28-crp reduction of this size.
Placebo: −0.57 points
Dose studied: 5 mg/day on days 1 and 2; 3 mg/day on days 3-5n = 992014
No randomized trial result
16 results from other study designs.
−15.6%
Mean uterine volume reduction, day 29 · Shown as a change. The study reports a mean uterine volume reduction, day 29 of this size. · cetrorelix 4 x 5 mg (SD 20.2)
Placebo (SD 32.1): −5.1%
Dose studied: 5 mg on days 1, 8, 15 and 224 weeksn not reported2007
No randomized trial result
49 results from other study designs.
1.6%
Patients not given hCG for threatening OHSS
n = 2732000
No randomized trial result
6 results from other study designs.